# Novelty Nobility

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novelty-nobility

- Industry: Biotechnology
- Headquarters: Seongnam, South Korea
- Website: www.noveltynobility.com
- Total disclosed funding: $50M
- Latest round: Series C (Nov 8, 2024)
- Investors on record: 21

## About

Based in Seongnam, South Korea, and founded in 2017 by Sang Gyu Park (CEO), Novelty Nobility Inc., is a biotech company that works on the development and discovery of therapeutic antibodies, antibody-drug conjugates (ADCs), and ADC linker technologies to cure cancer and other medical conditions. In May 2022, Novelty Nobility Inc. raised KRW 34.1 billion in Series B funding from new investors Albatross Investment, KB Investment, KB Securities, NH Investment & Securities, Samho Green Investment, SL investment, and others.

The company is working on four drugs: NN2101, a monoclonal retinal disease therapeutic drug, NN3201, an antibody drug conjugate anti-cancer drug, NN2802, a chronic urticaria treatment drug, and NN3206, an ADC cancer drug with a pan-RAS inhibitor concept. Furthermore, the company has a PREXISE-D monoclonal antibody (mAbs) design and discovery platform that conducts human and mouse experiments to develop multi-purpose antibodies. PREXISETM-L is another patented, proprietary linker platform technology of the company that allows for the site-specific conjugation of various payloads to an intact antibody.

Novelty Nobility Inc. intends to use the May 2022 funding for its retinal disease treatment's initial clinical trials and the preclinical development of its anticancer drug.

## Funding rounds

- Series C, Nov 8, 2024, $17M — Shinhan Venture Investment, KB Investment, SL Investment, KDB Capital, Samho Green Investment, Solidus Investment, Brave New Investment
- Series B, May 12, 2022, $25M — KB Investment, SL Investment, HB Investment, Samho Green Investment, Solidus Investment, Mirae Asset Venture Investment, NH Investment & Securities, Albatross Investment, Medici Investment, K2 Investment Partners, BSK Investment
- Series A, Jan 31, 2020, $8.4M — Shinhan Venture Investment, P&I Investment, QUAD Ventures, BSK Investment, Widwin Investment, JX Partners, Ulmus Investment, Medytox Venture Investment, Kingo Investment Partners

## Investors

- Shinhan Venture Investment (https://capitalatlas.ai/funds/shinhan-venture-investment) — Series A, Series C
- P&I Investment (https://capitalatlas.ai/funds/p-i-investment) — Series A
- QUAD Ventures (https://capitalatlas.ai/funds/quad-ventures) — Series A
- BSK Investment (https://capitalatlas.ai/funds/bsk-investment) — Series A, Series B
- Widwin Investment (https://capitalatlas.ai/funds/widwin-investment) — Series A
- JX Partners (https://capitalatlas.ai/funds/jx-partners) — Series A
- Ulmus Investment (https://capitalatlas.ai/funds/ulmus-investment) — Series A
- Medytox Venture Investment (https://capitalatlas.ai/funds/medytox-venture-investment) — Series A
- Kingo Investment Partners (https://capitalatlas.ai/funds/kingo-investment-partners) — Series A
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series B, Series C
- SL Investment (https://capitalatlas.ai/funds/sl-investment) — Series B, Series C
- HB Investment (https://capitalatlas.ai/funds/hb-investment) — Series B
- Samho Green Investment (https://capitalatlas.ai/funds/samho-green-investment) — Series B, Series C
- Solidus Investment (https://capitalatlas.ai/funds/solidus-investment) — Series B, Series C
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series B
- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Series B
- Albatross Investment (https://capitalatlas.ai/funds/albatross-investment) — Series B
- Medici Investment (https://capitalatlas.ai/funds/medici-investment) — Series B
- K2 Investment Partners (https://capitalatlas.ai/funds/k2-investment-partners) — Series B
- KDB Capital (https://capitalatlas.ai/funds/kdb-capital) — Series C
- Brave New Investment (https://capitalatlas.ai/funds/brave-new-investment) — Series C